[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354297-105":59,"doc-detail-354297-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","erbb-receptor-feedback-inhibitor-1-mutation-in-biliary-tract-cancers-turning-resistance-into-response","ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers - Turning Resistance Into Response","","Purpose: EGFR alterations in a subset of biliary tract cancers (BTCs) relate to progression and poor prognosis, yet targeted treatments remain limited. ERRFI1 encodes MIG6, an EGFR inhibitor, and may serve as a predictive biomarker. Methods: Retrospective multicenter analysis of BTC patients with ERRFI1 alterations; variant allele frequencies, co-alterations, and outcomes (response, TTP, OS, safety, tumor-marker kinetics) were collected. Results: 14 patients, all intrahepatic cholangiocarcinoma; EGFR TKIs in 8 showed responses and disease control with manageable toxicity. Conclusion: ERRFI1 mutations are actionable biomarkers supporting routine testing.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/erbb-receptor-feedback-inhibitor-1-mutation-in-biliary-tract-cancers-turning-resistance-into-response/354297/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/erbb-receptor-feedback-inhibitor-1-mutation-in-biliary-tract-cancers-turning-resistance-into-response/354297.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main objective regarding ERRFI1 in BTC?","Question",{"text":113,"@type":114},"To determine whether loss-of-function mutations in ERRFI1 can predict response to EGFR-targeted therapy in biliary tract cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients selected and what outcomes were evaluated?",{"text":118,"@type":114},"Patients with BTC harboring ERRFI1 alterations were included in a retrospective multicenter study, and outcomes included response, time to progression, overall survival, safety, and tumor-marker kinetics.",{"name":120,"@type":111,"acceptedAnswer":121},"What clinical benefit was observed with EGFR tyrosine kinase inhibitor therapy?",{"text":122,"@type":114},"Among patients receiving EGFR-directed therapy, disease control was achieved in most cases, with a median time to progression of 7 months and generally manageable toxicities.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354297,1790193943,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Original Reports | Precision Medicine  \nErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response  \nSupriya Peshin, MD1  ; Fen Saj, MD, DM2  ; Pashtoon M. Kasi, MD, MS3  ; Felicity David, MBChB, MPH2; Janio Szklaruk, MD, PhD4; Quentin Kimana, MBChB2; Shubham Pant, MD2  ; Sunyoung S. Lee, MD, PhD2; Jennifer J. Knox, MD, FRCPC5 ; Mitesh J. Borad, MD6  ; and Milind Javle, MD2   \nDOI [https://doi.org/10.1200/PO-25-00673](https://doi.org/10.1200/PO-25-00673)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | EGFR alterations occur in a subset of biliary tract cancers (BTCs) and are often linked to disease progression and poor prognosis, yet targeted approaches remain underexplored. ERRFI1 , encoding the epidermal growth factor receptor (EGFR) inhibitor MIG6, is mutated in various cancers, including BTC, representing a potential predictive biomarker. We investigated whether lossofERRFI1 function may enhance sensitivity to EGFR-targeted tyrosine kinase inhibitors (TKIs), presenting a potential therapeutic opportunity. |\n| METHODS | This is a retrospective multicenter study of patients with BTC harboring ERRFI1 alterations. Data were extracted from electronic health records following institutional approval. ERRFI1 alterations were classiﬁed based on the alteration type, variant allele frequencies were documented, and coalterations were analyzed. Treatment outcomes including response, time to progression (TTP), overall survival (OS), safety proﬁles, and tumor marker kinetics were noted. |\n| RESULTS | Fourteen BTC patients with ERRFI1 mutations were identiﬁed in our database; the median age was 50 years, 64% were males; all cases were intrahepatic cholangiocarcinomas. Common coalterations includedIDH1 (36%), TP53 (29%), and ARID1A (29%) . All patients received gemcitabine-cisplatin as ﬁrst-line treatment, and 79% received immune checkpoint inhibitors. Eight patients (57%) received EGFR TKIs. Best responses to EGFR therapy included three partial responses (2 responses lasting >20 months), four stable diseases, and one progressive disease. The median TTP was 7 months (95% CI, 6 to 21 months) . Treatment was well-tolerated: toxicities included rash (n 5 2), transaminitis (n 5 1), and diarrhea (n 5 1) . The median OS was 20 months (95% CI: 8-36 months); 50% remained alive at last follow-up. |\n| CONCLUSION | ERRFI1 mutations represent actionable biomarkers in BTC, with EGFR-targeted therapy demonstrating meaningful clinical beneﬁt in this heavily pretreated population. These ﬁndings support integration of ERRFI1 testing into routine molecular proﬁling of BTC and other EGFR-driven malignancies. |\n\nACCOMPANYING CONTENT  \n Appendix  \n Data Sharing Statement  \nAccepted April 15, 2026  \nPublished June 3, 2026  \nJCO Precis Oncol 10:e2500673 © 2026 by American Society of Clinical Oncology  \nLicensed under the Creative Commons Attribution 4.0 License  \nINTRODUCTION  \nBiliary tract cancers (BTCs), some of the most challenging malignancies in oncology, are characterized by their aggressive behavior and limited treatment options.1 While ﬁrst-line chemoimmunotherapy offers modest survival beneﬁts, most patients progress, underscoring the need for effective second-line strategies.2 Recent advances in comprehensive genomic proﬁling have revealed actionable molecular targets in nearly 40% of cases. However, many patients lack these targets or develop resistance, highlighting the need for additional biomarkers and therapeutic avenues.3,4  \nEpidermal growth factor receptor (EGFR) pathway dysregulation contributes signiﬁcantly to BTC pathogenesis.5 EGFR-targeted approaches have not been successful for treatment in unselected BTC populations.6,7 EGFR mutations occur infrequently, but have been reported in gallbladder cancer, where they represent actionable targets.8 ,9 An underrecognized but potentially important component of this signaling axis is the ErbB receptor feedback inhibitor 1 (ERRFI1) gene, which encodes mitoge","cbCaiv6lWCaiZO8Y","https://ap.wps.com/l/cbCaiv6lWCaiZO8Y","pdf",3083022,11,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What was the study’s main objective regarding ERRFI1 in BTC?\",\"answer\":\"To determine whether loss-of-function mutations in ERRFI1 can predict response to EGFR-targeted therapy in biliary tract cancers.\"},{\"question\":\"How were patients selected and what outcomes were evaluated?\",\"answer\":\"Patients with BTC harboring ERRFI1 alterations were included in a retrospective multicenter study, and outcomes included response, time to progression, overall survival, safety, and tumor-marker kinetics.\"},{\"question\":\"What clinical benefit was observed with EGFR tyrosine kinase inhibitor therapy?\",\"answer\":\"Among patients receiving EGFR-directed therapy, disease control was achieved in most cases, with a median time to progression of 7 months and generally manageable toxicities.\"}]","ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers - Turning Resistance Into Response | PDF",1790109943,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4414c01249f635c62add18b9c9d0ef19.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3da246df4492650f717b1e55bc3eb59.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd7a6f530bd345327d22e5c7cfd4f547.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c4dbd3bb2ae6e27f10a10da57e19455.webp",980,1311]